SCI Pharmtech Inc (TW:4119) — Market Cap & Net Worth
Market Cap & Net Worth: SCI Pharmtech Inc (4119)
SCI Pharmtech Inc (TW:4119) has a market capitalization of $224.40 Million (NT$7.12 Billion) as of September 17, 2026. Listed on the TW stock exchange, this Taiwan-based company holds position #16180 globally and #740 in its home market, demonstrating a 9.16% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SCI Pharmtech Inc's stock price NT$59.60 by its total outstanding shares 119508634 (119.51 Million). Also see 4119 total assets for a full breakdown of the balance sheet.
SCI Pharmtech Inc Market Cap History: 2015 to 2026
SCI Pharmtech Inc's market capitalization history from 2015 to 2026. Data shows change from $295.31 Million to $224.40 Million (-1.00% CAGR). Also see how efficiently does SCI Pharmtech Inc generate cash for how efficiently the company converts equity into cash flow.
SCI Pharmtech Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SCI Pharmtech Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 4119 stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.14x
SCI Pharmtech Inc's market cap is 0.14 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.71x
SCI Pharmtech Inc's market cap is 1.71 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $250.50 Million | $1.90 Billion | $416.95 Million | 0.13x | 0.60x |
| 2017 | $197.39 Million | $1.30 Billion | $190.98 Million | 0.15x | 1.03x |
| 2018 | $248.43 Million | $1.94 Billion | $447.24 Million | 0.13x | 0.56x |
| 2019 | $394.43 Million | $2.36 Billion | $571.10 Million | 0.17x | 0.69x |
| 2020 | $314.07 Million | $2.69 Billion | $360.12 Million | 0.12x | 0.87x |
| 2021 | $315.59 Million | $864.22 Million | $55.70 Million | 0.37x | 5.67x |
| 2022 | $366.31 Million | $899.74 Million | $308.78 Million | 0.41x | 1.19x |
| 2023 | $364.47 Million | $1.20 Billion | $294.72 Million | 0.30x | 1.24x |
| 2024 | $341.13 Million | $1.52 Billion | $534.68 Million | 0.22x | 0.64x |
| 2025 | $183.36 Million | $1.34 Billion | $107.37 Million | 0.14x | 1.71x |
Competitor Companies of 4119 by Market Capitalization
Companies near SCI Pharmtech Inc in the global market cap rankings as of September 17, 2026. Review 4119 intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to SCI Pharmtech Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
SCI Pharmtech Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, SCI Pharmtech Inc's market cap moved from $295.31 Million to $ 224.40 Million, with a yearly change of -1.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$224.40 Million | +22.38% |
| 2025 | NT$183.36 Million | -46.25% |
| 2024 | NT$341.13 Million | -6.40% |
| 2023 | NT$364.47 Million | -0.50% |
| 2022 | NT$366.31 Million | +16.07% |
| 2021 | NT$315.59 Million | +0.48% |
| 2020 | NT$314.07 Million | -20.37% |
| 2019 | NT$394.43 Million | +58.77% |
| 2018 | NT$248.43 Million | +25.86% |
| 2017 | NT$197.39 Million | -21.20% |
| 2016 | NT$250.50 Million | -15.18% |
| 2015 | NT$295.31 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of SCI Pharmtech Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $224.40 Million USD |
| MoneyControl | $224.40 Million USD |
| MarketWatch | $224.40 Million USD |
| marketcap.company | $224.40 Million USD |
| Reuters | $224.40 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About SCI Pharmtech Inc
SCI Pharmtech, Inc. engages in the research and development, manufacture, and sale of active pharmaceutical ingredients, intermediates, and specialty chemicals. The company offers active pharmaceutical ingredients, including adenine, articaine HCl, atomoxetine HCl, bisoprolol hemifumarate, brinzolamide, buprenorphine and buprenorphine HCl, cannabidol, divalproex sodium, duloxetine HCl, hydroxychl… Read more